Treatment of Non-Tuberculous Mycobacterial Infections With Interferon Gamma
Completed · Phase 2
Conditions studied: Healthy, Mycobacterium Infections, Atypical
In brief
This is an open label study to determine the effects of the administration of Interferon-gamma on the clinical condition and immune function of patients with severe, treatment refractory non-tuberculosis mycobacterial infections. The study drug (interferon gamma) will be administered subcutaneously three times a week at 0.05 mg/m(2) for one year. We may also collect blood from the relatives of these patients and normal volunteers in order to characterize the genetic basis, if any, of our patients' disorders.
Key facts
- Study ID
- NCT00001318
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 60
- Starts
- 1992-08-01
- Expected to finish
- 2000-11-01
- Last updated by the study team
- 2008-03-04
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- National Institute of Allergy and Infectious Diseases (NIAID) — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.